Sign In
Buy NMTC
NeuroOne Medical Technologies Earnings Calls
| Release date | May 12, 2026 |
| EPS estimate | -$0.227 |
| EPS actual | -$0.250 |
| EPS Surprise | -10.29% |
| Revenue estimate | 2.578M |
| Revenue actual | 2.391M |
| Revenue Surprise | -7.24% |
| Release date | Feb 17, 2026 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.180 |
| EPS Surprise | 25.00% |
| Revenue estimate | 2.656M |
| Revenue actual | 2.893M |
| Revenue Surprise | 8.93% |
| Release date | Dec 17, 2025 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.0500 |
| EPS Surprise | -25.00% |
| Revenue estimate | 2.47M |
| Revenue actual | 2.715M |
| Revenue Surprise | 9.92% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0300 |
| EPS Surprise | 40.00% |
| Revenue estimate | 1.817M |
| Revenue actual | 1.696M |
| Revenue Surprise | -6.64% |
Last 4 Quarters for NeuroOne Medical Technologies
Below you can see how NMTC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $4.98 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0300 |
| EPS surprise | 40.00% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $4.49 |
| Aug 11, 2025 | $4.43 |
| Aug 12, 2025 | $4.78 |
| Aug 13, 2025 | $5.16 |
| Aug 14, 2025 | $4.98 |
| Aug 15, 2025 | $4.92 |
| Aug 18, 2025 | $4.98 |
| Aug 19, 2025 | $4.85 |
| Aug 20, 2025 | $4.51 |
| 4 days before | 10.87% |
| 4 days after | -9.48% |
| On release day | -1.23% |
| Change in period | 0.361% |
| Release date | Dec 17, 2025 |
| Price on release | $4.01 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.0500 |
| EPS surprise | -25.00% |
| Date | Price |
|---|---|
| Dec 11, 2025 | $3.51 |
| Dec 12, 2025 | $3.94 |
| Dec 15, 2025 | $3.97 |
| Dec 16, 2025 | $4.24 |
| Dec 17, 2025 | $4.01 |
| Dec 18, 2025 | $4.30 |
| Dec 19, 2025 | $4.41 |
| Dec 22, 2025 | $4.82 |
| Dec 23, 2025 | $4.30 |
| 4 days before | 14.19% |
| 4 days after | 7.19% |
| On release day | 7.20% |
| Change in period | 22.39% |
| Release date | Feb 17, 2026 |
| Price on release | $4.07 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.180 |
| EPS surprise | 25.00% |
| Date | Price |
|---|---|
| Feb 10, 2026 | $4.81 |
| Feb 11, 2026 | $4.92 |
| Feb 12, 2026 | $4.52 |
| Feb 13, 2026 | $4.88 |
| Feb 17, 2026 | $4.07 |
| Feb 18, 2026 | $4.08 |
| Feb 19, 2026 | $4.25 |
| Feb 20, 2026 | $4.08 |
| Feb 23, 2026 | $4.08 |
| 4 days before | -15.32% |
| 4 days after | 0.147% |
| On release day | 0.162% |
| Change in period | -15.19% |
| Release date | May 12, 2026 |
| Price on release | $4.39 |
| EPS estimate | -$0.227 |
| EPS actual | -$0.250 |
| EPS surprise | -10.29% |
| Date | Price |
|---|---|
| May 06, 2026 | $4.30 |
| May 07, 2026 | $4.54 |
| May 08, 2026 | $4.76 |
| May 11, 2026 | $4.33 |
| May 12, 2026 | $4.39 |
| May 13, 2026 | $4.51 |
| May 14, 2026 | $4.60 |
| May 15, 2026 | $4.21 |
| May 18, 2026 | $4.53 |
| 4 days before | 2.09% |
| 4 days after | 3.19% |
| On release day | 2.73% |
| Change in period | 5.35% |
NeuroOne Medical Technologies Earnings Call Transcript Summary of Q1 2026
NeuroOne reported sequential revenue growth in Q1 FY2026 with product revenue of $2.9M (down year-over-year due to prior-year Zimmer stocking). Management projects FY2026 revenue of at least $10.5M (≥17% growth vs FY2025). Clinical adoption of the OneRF brain ablation system accelerated — nearly half of all ablations since launch occurred in Q1 — and the company is establishing a patient registry. The OneRF trigeminal nerve system received FDA 510(k) clearance; a limited commercial launch treated 9 patients across 3 centers with all patients reported pain-free to date, and diligence with a strategic partner is underway. The drug-delivery program was accelerated (devices expected for investigational/animal use in Q3 FY2026, ~6 months earlier than planned) and advisory boards and pharma discussions are in progress. Two lower-back pain programs (percutaneous paddle electrode and basivertebral nerve ablation) are advancing with upcoming animal studies and strategic discussions. Board strengthened with Jason Mills (Penumbra/Boston Scientific background). Financials: product gross margin ~54.2%, total OpEx ~$3.3M, net loss $1.4M ($0.03/share). Cash was $3.6M at 12/31/25; management states the company is funded through FY2026 (potentially longer if milestones are met). No debt outstanding. Management will attend investor conferences and plans continued program updates.
